Theravance Biopharma, Inc. (NASDAQ:TBPH) reached 68.91% versus a 1-year low price of $21.97. The stock was last seen -4.72% lower, reaching at $37.11 on Jul. 14, 2017. At recent session, the prices were hovering between $37.08 and $39.37. This company shares are 9.7% off its target price of $40.71 and the current market capitalization stands at $1.99B. The recent change has given its price a -4.66% deficit over SMA 50 and -14.57% deficit over its 52-week high. The stock witnessed -0.88% declines, -1.93% declines and 12.32% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found TBPH’s volatility during a week at 4.65% and during a month it has been found around 4.22%.

Theravance Biopharma, Inc. (TBPH) Top Holders

Institutional investors currently hold around $1.76 billion or 86.2% in TBPH stock. Look at its top three institutional owners. Woodford Investment Management Ltd owns $416.96 million in Theravance Biopharma, Inc., which represents roughly 20.95% of the company’s market cap and approximately 23.65% of the institutional ownership. Similar statistics are true for the second largest owner, Baupost Group Llc/Ma, which owns 9,273,991 shares of the stock are valued at $361.22 million. The third largest holder is Fmr Llc, which currently holds $266.59 million worth of this stock and that ownership represents nearly 13.4% of its market capitalization.

Theravance Biopharma, Inc. 13F Filings

At the end of March 2017 reporting period, 45 institutional holders increased their position in Theravance Biopharma, Inc. (NASDAQ:TBPH) by some 3,648,734 shares, 41 decreased positions by 1,732,504 and 21 held positions by 39,886,140. That puts total institutional holdings at 45,267,378 shares, according to SEC filings. The stock grabbed 12 new institutional investments totaling 835,359 shares while 13 institutional investors sold out their entire positions totaling 915,887 shares.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Insider Trades

Multiple company employees have indulged in significant insider trading. Theravance Biopharma, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that SVP Clin Dev & Chief Med Ofc HAUMANN BRETT K has sold 14,000 shares of Theravance Biopharma, Inc. (TBPH) in trading session dated Mar. 07, 2017. These shares are worth $441,000 and were traded at $31.5 each. The SEC filing shows that Shafer Bradford J performed a sale of 26,829 shares. The EVP, Gen. Counsel, Secretary disposed these shares by way of transaction on Mar. 03, 2017. The company’s shares were given away at $31.86 per share worth to an income of some $854,772 on account of Shafer Bradford J.

SVP Clin Dev & Chief Med Ofc, HAUMANN BRETT K, sold 4,491 common shares of Theravance Biopharma, Inc. (TBPH) in the open market. In a transaction dated Aug. 25, 2016, the shares were put up for sale at an average price of $27.99, raking in a sum of $125,703. After this sale, 188,293 common shares of TBPH are directly owned by the insider, with total stake valued at $6,987,553.

In the transaction dated Aug. 22, 2016, the great number of shares disposed came courtesy the EVP, Gen. Counsel, Secretary; Shafer Bradford J disposed a total of 49,122 shares at an average price of $27.46, amounting to approximately $1,348,890. The insider now directly owns 195,730 shares worth $7,263,540.

Theravance Biopharma, Inc. (TBPH) Analyst Guide

Several analysts have released their opinion on Theravance Biopharma, Inc. (NASDAQ:TBPH), with 3 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 1 sell and 1 strong sell ratings, collectively assigning a 2.33 average brokerage recommendation.

Previous articleAnalyzing Stocks On Analyst Opinion: Smart Sand Inc. (SND), Tractor Supply Company (TSCO)
Next articleCHF Solutions, Inc. (CHFS) loses confidence of 8 hedge fund managers